Skip to main content

Table 2 Comparison of Survival times (months) calculated using Kaplan–Meier analysis and the groups with the Log-rank test

From: Survival in patients with multiple myeloma: evaluation of possible associations with bone marrow fibrosis and investigation of factors independently associated with survival

 

n

Exitus

Mean ± Standard Error (95% Confidence Interval)

5-year survival (%)

p

Overall survival

72

24

81.54 ± 7.01 (67.80–95.29)

56.5 ± 7.4

N/A

Age

     

 < 60

28

7

58.30 ± 5.45 (47.63–68.98)

56.4 ± 14.2

0.295

 ≥ 60

44

17

77.69 ± 8.80 (60.45–94.93)

55.1 ± 8.6

 

Sex

     

 Male

39

13

83.22 ± 9.17 (65.25–101.19)

59.0 ± 9.2

0.878

 Female

33

11

75.77 ± 10.42 (55.34–96.19)

52.0 ± 12.2

 

Comorbidity

     

 No

26

7

83.75 ± 12.80 (58.67–108.84)

54.2 ± 15.5

0.374

 Yes

46

17

71.59 ± 7.70 (56.49–86.69)

55.1 ± 8.5

 

Type

     

 Heavy chain

58

23

75.08 ± 7.72 (59.94–90.21)

50.4 ± 7.9

0.051

 Light chain

14

1

70.36 ± 4.47 (61.59–79.13)

92.9 ± 6.9

 

Stage

     

 Others

19

1

117.77 ± 6.95 (104.15–131.39)

92.3 ± 7.4

0.003

 Stage III (A/B)

47

22

62.21 ± 7.53 (47.46–76.96)

42.6 ± 8.8

 

Lytic lesion

     

 No

19

7

49.68 ± 7.80 (34.39–64.97)

58.3 ± 12.6

0.861

 Yes

33

16

52.19 ± 6.24 (39.96–64.42)

41.3 ± 10.2

 

Plasmacytoma

     

 No

48

16

79.97 ± 8.91 (62.50–97.44)

56.7 ± 8.9

0.683

 Yes

22

8

75.75 ± 10.32 (55.53–95.98)

53.8 ± 13.5

 

Hypercalcemia

     

 No

59

17

86.87 ± 7.65 (71.88–101.86)

62.3 ± 8.0

0.023

 Yes

9

6

32.94 ± 7.90 (17.46–48.43)

19.4 ± 16.2

 

High creatinine (> 2)

     

 No

53

14

89.86 ± 7.89 (74.39–105.33)

64.4 ± 8.5

0.012

 Yes

18

10

39.07 ± 7.18 (25.00–53.13)

28.7 ± 14.5

 

Bone marrow fibrosis level

     

 0

15

4

85.27 ± 11.77 (62.20–108.34)

70.9 ± 12.4

0.730

 1–4

55

18

82.66 ± 7.96 (67.07–98.26)

58.0 ± 8.3

 

Response to treatment (primary line)

     

 Others

25

12

48.45 ± 7.64 (33.47–63.43)

34.7 ± 13.6

0.003

 VGPR & CR

33

5

105.31 ± 7.92 (89.79–120.82)

78.5 ± 8.8

 

Autologous stem cell transplantation

     

 No

36

16

48.98 ± 6.90 (35.45–62.51)

42.2 ± 11.1

0.007

 Yes

35

7

99.64 ± 8.35 (83.28–116.01)

73.6 ± 8.8

 
  1. p values marked with bold indicate statistically significant differences between the groups